'Nothing escapes our scientists': A handful of biotechs gear up work on monkeypox
Two years after biotech and pharma sprung to action to create vaccines and therapies in record time for the rapidly circulating Covid-19 pandemic, a handful of drug developers and vaccine makers are considering their role in preventing and treating future cases of the WHO’s latest public health emergency: monkeypox.
The virus, which can cause painful lesions, has been recorded in a little more than 44,500 people worldwide, nearly 16,000 of those in the US, as of a Monday CDC update. As compared to the early days of Covid-19, the US already has approved vaccines and a smallpox antiviral available under expanded use to curb and treat monkeypox.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.